Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label Study to Evaluate the Immunogenicity, Tolerability and Safety of an Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 Years and Above

NCT00992212 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT00992212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00992212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label Study to Evaluate the Immunogenicity, Tolerability and Safety of an Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 Years and Above
Lead sponsor
Novartis Vaccines
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2009
Completion date
November 30, 2009
Enrollment
418 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pandemic influenza disease